MedPath

Effects of Added D-fagomine on Glycaemic Responses to Sucrose

Not Applicable
Completed
Conditions
Reduction of Post-prandial Glycaemic Response
Interventions
Other: D-fagomine
Registration Number
NCT01811303
Lead Sponsor
Bioglane
Brief Summary

The purpose of this study is to determine whether D-fagomine affects glycaemic responses to sucrose (commercial white sugar)and quantify the response

Detailed Description

This is a two treatment randomized double-blind crossover study, with each test product replicated twice.

Randomization: Subjects will be randomized to a Williams Latin square design balanced for treatment order.

Washout: 2 days or more (may return on day 3)

Run-in: High carbohydrate diet guidance (\>150 g/d) 1 day before treatment, recommend same sized dinner the previous night (no food record collection required)

Drop-outs: Subjects who have dropped out before visit 2 will be replaced by another subject randomized in their place (the new subject will complete all treatments)

Subjects will report after an overnight (12 hour) fast for baseline sample collection, and will consume the test product in a fasted state.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
14
Inclusion Criteria
  • Male or female (not less than 40% Male)
  • Aged 18 - 55 years
  • Have a body mass index between 18.5 to 29.99 kg/m2
  • Healthy, non-diabetic, no gastric bypass surgery
  • Have a fasting plasma glucose (finger-stick) <100 mg/dl (<5.5 mmol/L)
  • Willing and able to provide written informed consent
Exclusion Criteria
  • Smokers
  • Allergic to dairy or soy

Study & Design

Study Type
INTERVENTIONAL
Study Design
CROSSOVER
Arm && Interventions
GroupInterventionDescription
D-fagomineD-fagomineMeasure the changes produced on the postprandial Glycaemic response to 50 g of sucrose containing 40 mg D-fagomine, in 200 ml water
ControlD-fagomineSucrose 50 g without d-fagomine, in 200 ml water
Primary Outcome Measures
NameTimeMethod
Postprandial Glycaemic Response Index120 minutes

On each intervention, the volunteer measured a baseline fasting blood sugar measurement for that day and repeated this approximately 5 minutes later so that two fasting measurements were obtained under the supervision of staff. All of the subsequent measurements were assessed against the average of the two baseline readings. Each subject was then presented with a test product and they were instructed to consume the whole amount within a fifteen-minute period. Each volunteer then took a blood sugar readings at 15, 30, 45, 60, 90 and 120 minutes following the initiation of consumption of the test product. Measurements were taken using the Ascensia Contour, Blood Glucose Monitoring Systems (Bayer), which analysed the blood sample and provided a blood glucose reading in mmol/l. The AUC is calculated using the trapezoid rule and the final outcome is the incremental area under the curve for the arm expressed as a percent of the average response for the control by the same subject.

Secondary Outcome Measures
NameTimeMethod
Maximum Blood Glucose Concentration (C Max) Over the BaselineUsually in the range of 30-45 minutes

Determine the glucose C max of Sucrose with D-fagomine over the baseline.

The blood glucose maximum concentration (C-Max) expressed in mmol/L of the average response for a 50g sucrose, over the baseline.

Calculation of the outcome is= (Measure glucose C-Max - Measure glucose baseline)

Trial Locations

Locations (1)

Reading Scientific Services Ltd.

🇬🇧

Reading, United Kingdom

© Copyright 2025. All Rights Reserved by MedPath